Introduction
The Inflation Reduction Act (IRA), signed in August 2022, gave Medicare the power to set prices for its highest-spending drugs for the first time. The program is no longer theoretical. The first 10 negotiated prices took effect on January 1, 2026, at discounts of 38% to 79% off list prices, and CMS estimated they would have cut net Medicare spending on those drugs by 22% (CMS's first-cycle negotiated price fact sheet). Fifteen more Part D drugs, Ozempic among them, carry negotiated prices from January 2027, and the third cycle pulled in Part B physician-administered drugs for the first time. From then on, up to 20 drugs are added every year.
For healthcare investment bankers, the IRA is not just a pricing rule. It is a structural force that changes how pharma companies build their portfolios, which modalities they buy, and how every Medicare-exposed revenue line is valued. This article covers how negotiation works, why the timing gap between small molecules and biologics drives deal theses, and how to reflect the law in a model. The mechanics of the statutory price ceiling are covered in IRA drug price negotiation and pharma valuation.
How Medicare Drug Price Negotiation Works
CMS ranks single source drugs (those without a generic or biosimilar competitor) by total Medicare Part B and Part D spending, removes excluded categories, and selects from the top of the list. A drug only qualifies once at least 7 years have passed since FDA approval for a small molecule, or 11 years since licensure for a biologic, the statutory test CMS restates in its third-cycle selection fact sheet. Negotiation then runs for about two years before the price applies, so the practical clocks are roughly 9 years of free pricing for small molecules and 13 years for biologics.
The word "negotiation" overstates the manufacturer's leverage. A company that refuses to sign an agreement or accept a price faces an excise tax that climbs from 65% to 95% of the drug's sales, equivalent to roughly 186% to 1,900% of the price itself, or it must pull all of its drugs from Medicare and Medicaid. Every manufacturer of a selected drug has signed on in each of the first three cycles, and on May 18, 2026, the Supreme Court declined to hear the drugmakers' constitutional challenges. Bankers therefore treat the process as durable administered pricing rather than a commercial negotiation.
- Maximum Fair Price (MFP)
The price Medicare pays for a drug selected under the IRA negotiation program. CMS builds its initial offer from the drug's clinical benefit, therapeutic alternatives, R&D costs and federal support received, and the final price cannot exceed a statutory ceiling tied to the drug's non-federal average manufacturer price. The MFP applies only to Medicare Part D and Part B use, not to commercial sales.
What the First Three Cycles Show
The selections so far show where the revenue pressure is landing.
| Cycle | Prices Effective | Drugs Selected | Notable Selections | Headline Result |
|---|---|---|---|---|
| First | January 2026 | 10 Part D | Eliquis, Jardiance, Xarelto, Januvia, Imbruvica | 38-79% off list; 22% lower net spending |
| Second | January 2027 | 15 Part D | Ozempic/Wegovy/Rybelsus, Trelegy Ellipta, Xtandi, Ibrance | 38-85% off list; about 44% lower net spending |
| Third | January 2028 | 15 Part B and Part D, plus first renegotiation (Tradjenta) | Trulicity, Biktarvy, Orencia, Entyvio, Xolair, Botox | Negotiated during 2026 |
Two lessons matter for valuation. First, the gap between list-price discounts and net savings is wide. Second-cycle prices sit 38% to 85% below 2024 list prices, yet CMS puts the aggregate reduction in net spending at about 44%, or 36% once Coverage Gap Discount Program payments are counted (CMS's second-cycle negotiated price fact sheet), because rebates had already cut deeply into many of these drugs. Second, the IRA sorts drugs by approval pathway, not molecular size. Semaglutide is a peptide approved under a new drug application, so it runs on the 7-year small molecule clock; that is how Ozempic took a 71% cut from its list price as early as the second cycle.
The Pill Penalty and Where Capital Is Moving
Industry argues the capital response is already visible. A study in *Therapeutic Innovation & Regulatory Science* found that early-stage investment in small molecules fell 68% from its pre-IRA peak among companies valued at $2 billion or less, with the sharpest declines in indications with high Medicare exposure. The study was sponsored by drugmakers including Merck, Amgen, AbbVie and Eli Lilly, so treat the exact figure as an industry-funded estimate of early-stage venture flows rather than a measure of total pharma R&D. Policy has moved in the same direction: Executive Order 14273, signed in April 2025, directed HHS to work with Congress to align small molecule treatment with biologics.
Impact on Pharma M&A Strategy
The IRA does not stop pharma M&A; the patent cliff supercycle still forces large buyers to replace expiring revenue. What the law changes is which assets win and how much buyers will pay for them.
| IRA Feature | M&A Consequence | Where It Shows Up |
|---|---|---|
| Pill penalty | Biologics valued above comparable small molecules | Pipeline deals tilt toward antibodies, ADCs and other licensed biologics |
| Medicare price step-down | Mature Medicare-heavy drugs lose value before patent expiry | Buyers haircut revenue tails of products near selection |
| Orphan drug exclusion | Rare disease assets keep pricing power longer | Premiums for orphan-first development programs |
| Part B inclusion | Infused and injected drugs now exposed | Orencia, Entyvio and Xolair selected in the third cycle |
Portfolio reshaping toward biologics. Biologics gain twice: four more years before a negotiated price, and the higher manufacturing and regulatory barriers that slow biosimilar competition. That combination favors targets with antibody, cell therapy and ADC platforms, and it helps explain why biologic pipelines have commanded richer valuations than small molecule programs with similar peak sales.
The orphan premium, widened in 2025. The original IRA only excluded drugs designated for a single rare disease and approved solely for that use. The 2025 budget reconciliation law (the One Big Beautiful Bill Act) widened the carve-out: drugs designated for multiple rare diseases are now excluded, and for a drug that later wins a non-orphan indication, the clock starts at that first non-orphan approval rather than at initial launch. The effect is large. Milliman's analysis notes that Keytruda and Opdivo would almost certainly have been selected for 2028 without the change, because both first launched in orphan cancer indications.
- Orphan Drug Exclusion
The IRA carve-out that keeps drugs approved only for rare diseases out of Medicare price negotiation. As amended in 2025, it covers drugs designated for one or more rare diseases, and it delays the negotiation clock for drugs that later expand into common indications until the first non-orphan approval.
For deal teams, this rewards orphan-first development: launch in a rare indication, build the label later, and push the negotiation clock back. Companies with orphan drug portfolios now carry a clearer regulatory moat, and buyers pay for it.
Small molecules still trade, at a price. Johnson & Johnson paid $14.6 billion for Intra-Cellular Therapies in 2025, and its lead asset, Caplyta, is an oral small molecule. Buyers have not abandoned pills; they price the shorter clock into the bid, so diligence on approval dates, Medicare mix and orphan status now sits alongside clinical and patent work.
Modeling the IRA in Pharma Valuations
In DCF and SOTP models for pharma companies, the IRA becomes a product-level adjustment rather than a single haircut. Each step depends on the one before it.
Classify the product
Identify whether it was approved under a new drug application (7-year clock) or licensed as a biologic (11-year clock), and check for orphan status that may delay or remove the clock.
Date the earliest price
Add roughly two years of negotiation to the selection eligibility date to find the first year a negotiated price could apply.
Test the selection odds
CMS selects only the highest Medicare spenders, so a mid-size product may never be picked; tie the probability to projected Medicare spend rank.
Apply the step-down
Cut Medicare net revenue, not list revenue, from the price-effective year onward, sized to the product's competition and clinical value.
Anchor the step-down on net savings evidence, such as the 22% and 44% aggregate net reductions from the first two cycles, not on headline list-price discounts. A simple illustration: a small molecule with $3 billion of US net sales, half from Medicare, taking a 40% net cut on Medicare volume loses $600 million of annual revenue, a 20% drop in US sales, years before patent expiry. The same cut on a biologic lands four years later, further out on the discount curve.
The negotiated price is no longer the only federal lever. CMS's GLOBE model, finalized on September 30, 2026, applies most-favored-nation (MFN) rebates to some Part B drugs from 2027 and excludes drugs with a negotiated IRA price in effect, so bankers now model two federal price mechanisms, not one (see the MFN and pharma tariff reset). Negotiated prices are also published, giving commercial payers a public reference point; treat any pull on commercial net prices as a downside case, not an established effect.
The next article covers the "One Big Beautiful Bill", the 2025 reconciliation law behind the orphan change above, along with its Medicaid cuts and the separate expiry of enhanced ACA subsidies.
